Bone Therapeutics: Information on the total number of voting rights and shares (December 2020) Read more about Bone Therapeutics: Information on the total number of voting rights and shares (December 2020)
Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study Read more about Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study
Bone Therapeutics announces pricing of private placement Read more about Bone Therapeutics announces pricing of private placement
Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent Read more about Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent
Bone Therapeutics, Cerhum, 3D-Side, mSKIL and IREC awarded €3M in BioWin supported funding to develop personalized, tissue engineered bone implants Read more about Bone Therapeutics, Cerhum, 3D-Side, mSKIL and IREC awarded €3M in BioWin supported funding to develop personalized, tissue engineered bone implants
Bone Therapeutics Provides Third Quarter 2020 Business Update Read more about Bone Therapeutics Provides Third Quarter 2020 Business Update
Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB Read more about Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB
Transparency notification received from S.R.I.W. SA and Sofipôle SA Read more about Transparency notification received from S.R.I.W. SA and Sofipôle SA
Bone Therapeutics: Information on the total number of voting rights and shares (October 2020) Read more about Bone Therapeutics: Information on the total number of voting rights and shares (October 2020)
Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study Read more about Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study